[go: up one dir, main page]

MX2019015204A - Uso del anticuerpo anti-cd70 argx-110 para el tratamiento de leucemia mieloide aguda. - Google Patents

Uso del anticuerpo anti-cd70 argx-110 para el tratamiento de leucemia mieloide aguda.

Info

Publication number
MX2019015204A
MX2019015204A MX2019015204A MX2019015204A MX2019015204A MX 2019015204 A MX2019015204 A MX 2019015204A MX 2019015204 A MX2019015204 A MX 2019015204A MX 2019015204 A MX2019015204 A MX 2019015204A MX 2019015204 A MX2019015204 A MX 2019015204A
Authority
MX
Mexico
Prior art keywords
acute myeloid
myeloid leukaemia
treat acute
antibody argx
argx
Prior art date
Application number
MX2019015204A
Other languages
English (en)
Inventor
Haard Hans De
Nicolas Leupin
Rompaey Luc Van
Adrian Ochsenbein
Carsten Riether
Original Assignee
Argenx Bvba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59462340&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019015204(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Argenx Bvba filed Critical Argenx Bvba
Publication of MX2019015204A publication Critical patent/MX2019015204A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001138—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se proporcionan métodos para el tratamiento de leucemia mieloide aguda (AML) y síndrome mielodisplásico (MDS), así como también composiciones y combinaciones adecuadas para usarse en dichos métodos.
MX2019015204A 2017-06-16 2018-06-18 Uso del anticuerpo anti-cd70 argx-110 para el tratamiento de leucemia mieloide aguda. MX2019015204A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1709677.7A GB2567613A (en) 2017-06-16 2017-06-16 Treatment for acute myeloid leukaemia
PCT/EP2018/066144 WO2018229303A1 (en) 2017-06-16 2018-06-18 Use of anti cd70 antibody argx-110 to treat acute myeloid leukaemia

Publications (1)

Publication Number Publication Date
MX2019015204A true MX2019015204A (es) 2020-08-17

Family

ID=59462340

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019015204A MX2019015204A (es) 2017-06-16 2018-06-18 Uso del anticuerpo anti-cd70 argx-110 para el tratamiento de leucemia mieloide aguda.

Country Status (23)

Country Link
US (2) US20190106498A1 (es)
EP (2) EP4389142A3 (es)
JP (2) JP7498564B2 (es)
KR (1) KR102799514B1 (es)
CN (1) CN110730789A (es)
AU (3) AU2018285731B2 (es)
BR (1) BR112019026795A2 (es)
CA (1) CA3063694A1 (es)
DK (1) DK3638696T5 (es)
EA (1) EA202090061A1 (es)
ES (1) ES2974678T3 (es)
FI (1) FI3638696T3 (es)
GB (2) GB2567613A (es)
HU (1) HUE066603T2 (es)
IL (2) IL321494A (es)
JO (1) JOP20190285A1 (es)
LT (1) LT3638696T (es)
MA (1) MA49377A (es)
MX (1) MX2019015204A (es)
PH (1) PH12019502477A1 (es)
PL (1) PL3638696T3 (es)
PT (1) PT3638696T (es)
WO (1) WO2018229303A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE039849T2 (hu) 2011-03-16 2019-02-28 Argenx Bvba CD70 elleni ellenanyagok
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
GB2567613A (en) * 2017-06-16 2019-04-24 Argenx Bvba Treatment for acute myeloid leukaemia
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
TWI848030B (zh) 2018-12-18 2024-07-11 比利時商阿根思公司 Ｃｄ７０組合治療
DK3946322T3 (da) * 2019-03-29 2023-11-27 Novocure Gmbh Fremgangsmåder til genoprettelse af sensitivitet over for ttfields i ttfields-resistente kræftceller med ptger3-inhibitorer
US11701428B2 (en) * 2019-04-29 2023-07-18 Immunogen, Inc. Therapeutic combinations comprising anti-CD123 immunoconjugates
US20220411478A1 (en) * 2019-09-16 2022-12-29 The General Hospital Corporation Cd70 targeted chimeric antigen receptor (car) t cells and uses thereof
TWI877278B (zh) * 2019-12-30 2025-03-21 美商思進公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
TW202214697A (zh) * 2020-06-30 2022-04-16 大陸商江蘇恆瑞醫藥股份有限公司 抗ｃｄ７０抗體及其應用
WO2022023379A1 (en) * 2020-07-28 2022-02-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for preventing and treating a cancer
IL300996A (en) * 2020-08-29 2023-04-01 argenx BV Treatment method for patients with reduced sensitivity to BCL-2 inhibitor
CN114685657B (zh) * 2020-12-31 2024-08-16 康诺亚生物医药科技（成都）有限公司 一种功能增强型抗体阻断剂的开发及其应用
CN114720358B (zh) * 2022-04-11 2022-09-27 浙江普罗亭健康科技有限公司 一种质谱流式血液肿瘤免疫分型中替代侧向散射光信号的抗体组合及应用
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1594542B1 (en) 2003-02-20 2010-06-30 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer
CA2583208C (en) 2004-10-15 2015-08-25 Seattle Genetics, Inc. Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders
JP5122441B2 (ja) 2005-04-19 2013-01-16 シアトル ジェネティックス， インコーポレイテッド ヒト化抗ｃｄ７０結合剤およびその使用
AU2006294663B2 (en) * 2005-09-26 2012-03-22 Medarex, Inc. Human monoclonal antibodies to CD70
IN2009KN02404A (es) 2006-12-14 2015-08-07 Medarex Inc
HUE039849T2 (hu) 2011-03-16 2019-02-28 Argenx Bvba CD70 elleni ellenanyagok
KR101920541B1 (ko) * 2011-05-31 2018-11-20 허치슨 바이오필름 메디컬 솔루션스 리미티드 세포 응집물의 분산 및 분리
US10208123B2 (en) 2012-06-19 2019-02-19 Ambrx, Inc. Anti-CD70 antibody drug conjugates
HUE033626T2 (en) * 2013-02-14 2017-12-28 Bristol Myers Squibb Co Tubulysin compounds, methods of preparation and use
MY198562A (en) 2015-11-03 2023-09-05 Janssen Biotech Inc Antibodies specifically binding pd-1 and their uses
GB2567613A (en) * 2017-06-16 2019-04-24 Argenx Bvba Treatment for acute myeloid leukaemia

Also Published As

Publication number Publication date
US20190106498A1 (en) 2019-04-11
EP3638696A1 (en) 2020-04-22
FI3638696T3 (fi) 2024-05-06
HUE066603T2 (hu) 2024-08-28
JP2024109951A (ja) 2024-08-14
EP4389142A2 (en) 2024-06-26
DK3638696T5 (da) 2024-08-26
AU2025201328A1 (en) 2025-03-20
JP7498564B2 (ja) 2024-06-12
US20250230252A1 (en) 2025-07-17
PT3638696T (pt) 2024-05-03
IL271266A (en) 2020-01-30
KR102799514B1 (ko) 2025-04-23
CA3063694A1 (en) 2018-12-20
EP3638696B1 (en) 2024-03-06
BR112019026795A2 (pt) 2020-06-30
CN110730789A (zh) 2020-01-24
MA49377A (fr) 2020-04-22
LT3638696T (lt) 2024-06-25
PH12019502477A1 (en) 2020-07-20
GB2567613A (en) 2019-04-24
IL321494A (en) 2025-08-01
EA202090061A1 (ru) 2020-04-13
EP4389142A3 (en) 2024-08-21
PL3638696T3 (pl) 2024-07-22
JP2020528044A (ja) 2020-09-17
AU2022200521A1 (en) 2022-02-17
ES2974678T3 (es) 2024-07-01
KR20200024823A (ko) 2020-03-09
GB201709677D0 (en) 2017-08-02
DK3638696T3 (da) 2024-05-06
JOP20190285A1 (ar) 2019-12-15
AU2025201328A2 (en) 2025-05-22
AU2018285731A1 (en) 2019-11-28
EP3638696B8 (en) 2024-06-26
GB201712273D0 (en) 2017-09-13
AU2018285731B2 (en) 2021-11-04
WO2018229303A1 (en) 2018-12-20
NZ758854A (en) 2025-05-30

Similar Documents

Publication Publication Date Title
MX2019015204A (es) Uso del anticuerpo anti-cd70 argx-110 para el tratamiento de leucemia mieloide aguda.
CO2020015255A2 (es) Métodos y composiciones para tratar el cáncer
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
EA202091540A1 (ru) Антитела к lilrb2
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
MX2016011619A (es) Anticuerpos anti-egfrviii y usos de los mismos.
CL2018003316A1 (es) Compuestos para la inhibición de k-ras y para el tratamiento del cáncer. (divisional solicitud 201702786)
CO2018006164A2 (es) Compuestos útiles como inhibidores de cinasa
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
CO2018006662A2 (es) Agonistas del receptor de apelina y métodos de uso
JOP20190194A1 (ar) مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان
MX2012013256A (es) Composiciones y metodos para el tratamiento de leucemia.
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
UY36419A (es) Composiciones farmacéuticas que contienen anticuerpos anti-cd38 para el tratamiento de la leucemia mieloide aguda
CL2016001082A1 (es) Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa
MX2018004515A (es) Agentes de anticuerpo especificos para cd19 humano y usos de los mismos.
PE20160167A1 (es) Composiciones y metodos para alterar la senalizacion del segundo mensajero
UY36075A (es) Derivados de tubulisina
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
MX373308B (es) Composiciones que comprenden anticuerpos anti-cd38 y carfilzomib.
AR119681A1 (es) Métodos de tratamiento del cáncer de mama con tucatinib
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
BR112019003130A2 (pt) agonista de ppargama para tratamento de cânceres de sangue
EA201591709A1 (ru) 5-бром-индирубины